Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

Liquidia Corporation will report its Q3 2025 financial results on November 3, 2025, with a subsequent webcast.

Quiver AI Summary

Liquidia Corporation, a biopharmaceutical company focused on innovative therapies for rare cardiopulmonary diseases, announced it will disclose its financial results for the third quarter of 2025 on November 3, 2025. A webcast will be held at 8:30 a.m. ET to discuss these results and provide a corporate update, which can be accessed on their website. Liquidia is known for its proprietary PRINT® Technology, having developed the approved drug YUTREPIA™ for treating pulmonary arterial hypertension and is also working on an investigational drug L606. The company continues to offer generic Treprostinil Injection for PAH. For more information, visit Liquidia's website.

Potential Positives

Liquidia Corporation is set to report its third quarter 2025 financial results, indicating transparency and an opportunity for stakeholders to assess the company's performance.
The company will discuss financial results and provide a corporate update during a webcast, promoting engagement with investors and the public.
Liquidia's focus on developing therapies for rare cardiopulmonary diseases positions it in a niche market with potential for significant impact and growth.
The approval and market presence of YUTREPIA™ showcases the company's capability in successfully bringing innovative therapies to the market.

Potential Negatives

Announcement of third quarter financial results could indicate challenges if the results are below market expectations.
The mention of ongoing development of investigational products may signal a reliance on future success rather than current profitability, which could raise concerns among investors.

FAQ

When will Liquidia Corporation report its financial results?

Liquidia Corporation will report its third quarter 2025 financial results on November 3, 2025.

How can I access the Liquidia Corporation webcast?

The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations starting at 8:30 a.m. ET.

What is Liquidia Corporation's focus in the biopharmaceutical industry?

Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, particularly pulmonary hypertension.

What product has Liquidia Corporation developed for pulmonary hypertension?

Liquidia has developed YUTREPIA™ (treprostinil) inhalation powder for treating pulmonary arterial hypertension and associated conditions.

Who can I contact for investor inquiries at Liquidia?

You can contact Jason Adair, Chief Business Officer, at 919-328-4350 or via email at [email protected].

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$LQDA Insider Trading Activity

$LQDA insiders have traded $LQDA stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales.

Here’s a breakdown of recent trading of $LQDA stock by insiders over the last 6 months:

PAUL B MANNING has made 0 purchases and 4 sales selling 670,837 shares for an estimated $18,957,475.
SCOTT MOOMAW (Chief Commercial Officer) has made 0 purchases and 7 sales selling 87,626 shares for an estimated $2,329,559.
MICHAEL KASETA (CFO and COO) has made 0 purchases and 6 sales selling 88,846 shares for an estimated $1,826,572.
ROGER JEFFS (Chief Executive Officer) has made 0 purchases and 4 sales selling 91,375 shares for an estimated $1,572,158.
RAMAN SINGH has made 0 purchases and 2 sales selling 53,024 shares for an estimated $1,395,624.
JASON ADAIR (Chief Business Officer) has made 0 purchases and 8 sales selling 37,711 shares for an estimated $945,596.
RAJEEV SAGGAR (Chief Medical Officer) has made 0 purchases and 5 sales selling 40,777 shares for an estimated $923,495.
RUSSELL SCHUNDLER (General Counsel) has made 0 purchases and 5 sales selling 26,121 shares for an estimated $485,306.
JOANNA HOROBIN sold 5,000 shares for an estimated $135,850
SARAH KREPP (Chief Human Resource Officer) has made 0 purchases and 3 sales selling 4,573 shares for an estimated $83,828.
DANA BOYLE (Chief Accounting Officer) has made 0 purchases and 3 sales selling 3,494 shares for an estimated $66,788.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$LQDA Hedge Fund Activity

We have seen 101 institutional investors add shares of $LQDA stock to their portfolio, and 85 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEERFIELD MANAGEMENT COMPANY, L.P. added 1,616,778 shares (+inf%) to their portfolio in Q2 2025, for an estimated $20,145,053
GOLDMAN SACHS GROUP INC added 1,555,774 shares (+180.6%) to their portfolio in Q2 2025, for an estimated $19,384,944
TYRO CAPITAL MANAGEMENT LLC added 1,241,839 shares (+inf%) to their portfolio in Q2 2025, for an estimated $15,473,313
VESTAL POINT CAPITAL, LP removed 1,227,403 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,293,441
CENTERBOOK PARTNERS LP added 982,778 shares (+811.7%) to their portfolio in Q2 2025, for an estimated $12,245,413
SHAY CAPITAL LLC added 705,758 shares (+inf%) to their portfolio in Q2 2025, for an estimated $8,793,744
INVESCO LTD. removed 614,407 shares (-94.7%) from their portfolio in Q2 2025, for an estimated $7,655,511

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$LQDA Analyst Ratings

Wall Street analysts have issued reports on $LQDA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 10/06/2025
Jefferies issued a "Buy" rating on 08/15/2025
Needham issued a "Buy" rating on 08/12/2025
Wells Fargo issued a "Overweight" rating on 06/12/2025
B of A Securities issued a "Buy" rating on 06/11/2025
Scotiabank issued a "Sector Outperform" rating on 05/28/2025
Oppenheimer issued a "Underperform" rating on 05/19/2025

To track analyst ratings and price targets for $LQDA, check out Quiver Quantitative's $LQDA forecast page.

$LQDA Price Targets

Multiple analysts have issued price targets for $LQDA recently. We have seen 9 analysts offer price targets for $LQDA in the last 6 months, with a median target of $35.0.

Here are some recent targets:

Andrew S. Fein from HC Wainwright & Co. set a target price of $35.0 on 10/06/2025
Amy Li from Jefferies set a target price of $43.0 on 08/15/2025
Ryan Deschner from Raymond James set a target price of $41.0 on 08/13/2025
Tiago Fauth from Wells Fargo set a target price of $31.0 on 08/13/2025
Serge Belanger from Needham set a target price of $36.0 on 08/12/2025
Jason Gerberry from B of A Securities set a target price of $23.0 on 06/11/2025
Greg Harrison from Scotiabank set a target price of $37.0 on 05/28/2025

Full Release

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations . A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT ^® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com .

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4350
[email protected]

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
[email protected]